Filing Flows › Corcept Therapeutics (CORT) › Q2 2026 › vs Q2 2025
Corcept Therapeutics (CORT) Q2 2026 vs Q2 2025 (year over year)
Corcept Therapeutics's revenue rose $61.7M (+32%) from $194M in Q2 2025 to $256M in Q2 2026. The biggest changes: Lifyorli +$47.6M (—); Hypercortisolism Products +$14.2M (+7%). Operating margin 16.1% against 13.7% (+2.4 pts).
Corcept Therapeutics, Q2 2026: revenue $256M (+32% year over year), operating margin 16.1%, net earnings $43.0M, operating cash flow $33.5M. The chart draws each line against Q2 2025, the increases inside each band.
Margins
| Q2 2026 | Q2 2025 | Change | |
|---|---|---|---|
| Operating margin | 16.1% | 13.7% | +2.4 pts |
| Net margin | 16.8% | 18.1% | -1.3 pts |
| Free cash flow margin | 12.1% | 22.8% | -10.6 pts |
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Hypercortisolism Products | $209M | $194M | $14.2M | +7% |
| Lifyorli | $47.6M | $0 | $47.6M | — |
| Revenue | $256M | $194M | $61.7M | +32% |
| Other income, net | $4.6M | $5.0M | −$386K | -8% |
| Operating profit | $41.3M | $26.7M | $14.6M | +55% |
| Costs & expenses | $215M | $168M | $47.1M | +28% |
| Pre-tax earnings | $45.9M | $31.7M | $14.2M | +45% |
| Cost of revenue | $4.1M | $3.4M | $628K | +18% |
| Research & development | $53.9M | $60.5M | −$6.6M | -11% |
| SG&A | $157M | $104M | $53.0M | +51% |
| Net earnings | $43.0M | $35.1M | $7.8M | +22% |
| Income tax | $2.9M | −$3.5M | $6.4M | — |
| Depreciation & amortization | $863K | $469K | $394K | +84% |
| Share-based compensation | $29.4M | $19.0M | $10.4M | +55% |
| Working capital & other | $39.7M | $10.3M | $29.4M | +284% |
| Operating cash flow | $33.5M | $44.3M | −$10.8M | -24% |
| Free cash flow (OCF − capex) | $31.0M | $44.2M | −$13.2M | -30% |
| Capital expenditures | $2.5M | $57K | $2.5M | 44× |
Questions
How much did Corcept Therapeutics's revenue grow year over year in Q2 2026?
Corcept Therapeutics's revenue rose $61.7M (+32%) from $194M in Q2 2025 to $256M in Q2 2026.
What drove Corcept Therapeutics's revenue change in Q2 2026?
Lifyorli +$47.6M (—); Hypercortisolism Products +$14.2M (+7%).